Revvity Launches Signals AI, a Native Agentic Framework for Accelerating Scientific R&D

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY) announced the continued evolution of artificial intelligence across its Revvity Signals software business with new and expanding AI capabilities. Built natively into the Signals One™ platform, new capabilities from Signals AI help scientists transform connected R&D data into understanding, decisions and action using natural language within their existing workflows. As scientific organizations generate increasing volumes of data acr.

Business Wire • 13 hours ago

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Revvity, Inc. (RVTY) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

Seeking Alpha • Jun 9, 2026

Why Is Revvity (RVTY) Up 2% Since Last Earnings Report?

Revvity (RVTY) reported earnings 30 days ago. What's next for the stock?

Zacks Investment Research • Jun 4, 2026

RVTY Expands Endocrine Diagnostics With FDA-Cleared Testosterone Assay

Revvity gains FDA clearance for IDS' Total Testosterone assay, expanding its automated endocrine testing platform for reproductive diagnostics.

Zacks Investment Research • May 14, 2026

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Revvity, Inc. (RVTY) Presents at Bank of America Global Healthcare Conference 2026 Transcript

Seeking Alpha • May 13, 2026

Revvity Receives FDA Clearance for Total Testosterone Assay Enabling Comprehensive Automated Testosterone Testing Solution

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc., through its subsidiary, Immunodiagnostic Systems (IDS), today announced that it received clearance from the U.S. Food and Drug Administration (FDA) for its Total Testosterone automated chemiluminescence immunoassay (ChLIA). This offering complements the Company's FDA-cleared ChLIA tests for free testosterone and sex hormone-binding globulin (SHBG), delivering a first of its kind, complete solution for testosterone-related disorders on a single pla.

Business Wire • May 13, 2026

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Revvity, Inc. (RVTY) Q1 2026 Earnings Call Transcript

Seeking Alpha • May 5, 2026

Revvity Announces Financial Results for the First Quarter of 2026

WALTHAM, Mass.--(BUSINESS WIRE)--Revvity, Inc. (NYSE: RVTY), today reported financial results for the first quarter ended April 5, 2026. The Company reported GAAP earnings per share from continuing operations of $0.37, as compared to $0.35 in the same period a year ago. Revenue for the quarter was $711 million, as compared to $665 million in the same period a year ago. GAAP operating income from continuing operations for the quarter was $76 million, as compared to $72 million for the same perio.

Business Wire • May 5, 2026

Revvity (RVTY) Q1 Earnings and Revenues Top Estimates

Revvity (RVTY) came out with quarterly earnings of $1.06 per share, beating the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $1.01 per share a year ago.

Zacks Investment Research • May 5, 2026

Compared to Estimates, Revvity (RVTY) Q1 Earnings: A Look at Key Metrics

While the top- and bottom-line numbers for Revvity (RVTY) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.

Zacks Investment Research • May 5, 2026